AU Patent

AU2015328411C1 — Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response

Assigned to Dana Farber Cancer Institute Inc · Expires 2022-03-03 · 4y expired

What this patent protects

The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.

USPTO Abstract

The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.

Drugs covered by this patent

selumetinib-sulfate (SELUMETINIB SULFATE)

Patent Metadata

Patent number: AU2015328411C1
Jurisdiction: AU
Classification: —
Expires: 2022-03-03
Drug substance claim: No
Drug product claim: No
Assignee: Dana Farber Cancer Institute Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.